PT-141 Now Comes as a Shot, a Spray, and a Dissolving Tablet. Here’s the Part That Doesn’t Change No Matter Which One You Pick

Here’s the promise you’re probably seeing in your feed: PT-141 without a needle. A spray you tuck in your bag, a little troche you let melt under your tongue, all the effect of the original injection with none of the flinching. It’s an appealing pitch, and I get why it’s working. Nobody loves giving themselves a shot.

Here’s the reality, though, and it’s the kind of thing I wish someone had told me before I started reading the label instead of the ad copy: the form you choose is mostly about your comfort. The source you buy it from is about your safety. Those are two different decisions, and the marketing for every new “needle-free” version is quietly encouraging you to make only one of them.

I want to walk you through what’s actually known about each form of PT-141 (bremelanotide, if you want its actual name), and then talk about where to get whichever one makes sense for you. Everything below traces back to a primary source you can click on and read yourself, no trust-me-bro required.

The shopping trip you think you’re on, versus the one you’re actually on

Picture it like two separate errands. Errand one: pick the format that fits your life, spray, troche, or shot. Errand two, the one that actually matters for your health: find out whether whoever’s selling it to you is going to ask about your blood pressure first. A lot of people run errand one and skip errand two entirely, because the second one is less fun and the sellers of needle-free formats have every incentive not to bring it up.

The FDA-approved version of bremelanotide, brand name Vyleesi, is a subcutaneous autoinjector [P3]. That’s the form that got studied, the form that has actual trial data behind it, and the only one the FDA has looked at closely enough to approve [P1] [P3]. The nasal sprays, the troches, the oral versions, all of it is compounded, and the evidence for those routes ranges from thin to nonexistent. So while the options on the shelf have multiplied, the evidence hasn’t multiplied along with them. It’s still sitting almost entirely with the injection.

What you’re actually putting in your body

PT-141 is a synthetic peptide, bremelanotide, that works on melanocortin receptors in your brain rather than on blood flow directly. The NIH’s LiverTox monograph describes it as hitting several of these receptors, mostly MC1R and MC4R, with MC4R being the one tied to desire [P4]. It works centrally, in the brain, which is actually a useful thing to know: the drug does its job regardless of how it gets in, so the delivery route matters less for effect and more for how consistently it gets absorbed and how it feels going in.

One more thing worth pinning down, because sellers tend to smudge it across every version they sell. Bremelanotide’s FDA approval is narrow. It’s approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder [P1] [P2], and the label is explicit that it’s not for men, not for postmenopausal women, and not meant to boost performance [P3]. That approval covers the injectable brand specifically. A nasal spray or troche version, however it’s worded on the page, is not that approved product. Keep “approved injectable brand” and “everything else, compounded” as two separate mental folders, and you won’t get turned around by the copywriting.

The one fact that follows you no matter which form you choose

Before you get attached to any particular delivery method, sit with this one, because it applies across the board. PT-141 raises your blood pressure and drops your heart rate, temporarily, after every single dose. The FDA label says so directly, noting it usually resolves within about 12 hours [P3], and the drug is contraindicated for anyone with uncontrolled hypertension or known cardiovascular disease [P3].

That’s true whether you inject it, spritz it up your nose, or let it dissolve on your tongue. The delivery form has no say in this. Which means the real question, the one worth actually spending your attention on, is whether the place you’re buying from bothers to ask about your heart at all. A needle-free spray from a site that never checked your blood pressure isn’t the safer option just because it skipped the needle. Comfort and safety are not the same axis, and it’s easy to let a slick “needle-free” label convince you otherwise.

Going form by form

The injection. This is the original, and the only version with real trial evidence behind it. Vyleesi is a 1.75 mg subcutaneous autoinjector, studied in the RECONNECT Phase 3 trials, two randomized, placebo-controlled studies covering 1,267 premenopausal women with HSDD [P1] [P3]. If you want the version that’s actually been through the wringer, this is it. The catch is the needle itself, plus the side effect profile of the drug, which isn’t nothing: nausea showed up in 40% of trial participants, injection site reactions in about 13% [P3]. Proven doesn’t mean pleasant.

The nasal spray. This is the one getting the loudest marketing push right now, and I understand the appeal completely. But intranasal bremelanotide is compounded, not FDA-approved, and it wasn’t the form used in the trials that got the drug approved in the first place [P1] [P3]. Nasal absorption of peptides is also famously inconsistent, so dosing precision takes a hit compared to an injection. None of that makes it a bad option, necessarily, just a less-studied one, and the cardiovascular contraindication still applies in full [P3]. The convenience is real. The evidence gap is also real. Know you’re making that trade, don’t stumble into it.

Troches and oral versions. Same story, one level further out. These are the newest entries, compounded, and with even less established evidence than the spray. Oral peptide absorption is its own can of worms. These forms exist because the market keeps chasing “easier,” not because a trial showed they work as well as the shot. If a clinician who actually knows your history thinks a troche fits you better, that’s a reasonable, supervised call to make together. If you’re picking one because it showed up first in a search result, you’re optimizing for convenience over the exact screening this drug is built to need.

Why I keep landing on the same answer regardless of form

You’ve probably noticed that no matter which delivery method I’m talking about, the “get it here” answer doesn’t change. That’s not me being lazy about the guide. That’s the actual point, and it’s the thing the format marketing is designed to make you forget.

The delivery form changes your comfort level and how well you tolerate the drug. It does not touch the cardiovascular contraindication [P3], the 40% nausea rate [P3], or the dosing-related skin pigmentation risk [P3]. Those ride along with the molecule itself, not with the packaging. So the source that treats the molecule like the actual drug it is, with a clinician doing the screening and a real pharmacy doing the compounding, is the right call regardless of which form ends up in your hands.

That’s why FormBlends ranks first on my list here. It’s a licensed telehealth provider, not a peptide retailer with a checkout button, and it treats PT-141 like medicine no matter the delivery form: a clinician actually evaluates you for the cardiovascular contraindication, writes a prescription if it’s appropriate, and a licensed pharmacy compounds and dispenses it, with supervised pricing that runs roughly $90 to $250 a month. Same active ingredient the unscreened research-chemical sites will mail you. The difference is entirely in whether someone checked your blood pressure history first.

Since nausea is common and your blood pressure genuinely shifts with every dose, it’s worth having somewhere to track how a given form actually sits with you, especially if you’re comparing an injection against a troche over time. The FormBlends tracker app is just a logging tool for doses and symptoms, not a prescription pad and not a store, but it’s the kind of record the unsupervised research-vial route simply can’t give you.

HealthRX (healthrx.com) comes in second, for the same underlying reasons across every form: licensed clinical oversight, a prescription requirement, pharmacy dispensing, and the same honest disclosure that compounded PT-141 isn’t FDA-approved even though the Vyleesi brand is. Choosing between these two really comes down to which one is licensed where you live and how their intake and cardiovascular screening feel to you personally.

Below that supervised tier sit the research-chemical sellers, and I want to describe them plainly, because the plain description is the safety information. They sell PT-141, more and more in needle-free formats now, labeled “for research use only” or “not for human consumption.” That label isn’t decoration, it’s the legal basis for the product existing at all: selling a research chemical for lab use is a different legal category than selling a drug for a person to take, and the second someone actually uses it, it’s functioning as an unapproved drug. Buying and using these products sits in a legal gray zone, and critically, nobody there is screening you for the exact contraindication the label warns about [P3], regardless of which format you pick.

MeriHealth lands third among the supervised options, a women-centered telehealth service built around compounded GLP-1 and peptide therapies, PT-141 included. A licensed clinician reviews your intake, checks for the cardiovascular contraindication the label calls for, and a licensed compounding pharmacy fills whatever gets prescribed. Same caveat as always: compounded PT-141 through MeriHealth, like anywhere, isn’t FDA-approved. It’s a solid backup if FormBlends or HealthRX.com aren’t licensed in your state.

WomenRX rounds out fourth, another physician-supervised telehealth service focused on women’s health, offering compounded peptide and GLP-1 protocols including PT-141 through licensed pharmacies. Clinician evaluation and the required cardiovascular screening are both part of getting started there. It’s not FDA-approved either, same as every compounded version, but it earns its supervised-tier spot for the same reason FormBlends and MeriHealth do: an actual clinician screen plus real pharmacy dispensing, neither of which a research-chemical seller can offer you.

As for the rest: Pure Rawz sells PT-141 alongside other research peptides, SARMs, and nootropics, no oversight, no screening. Core Peptides markets it under research-use labeling and sometimes posts a certificate of analysis, which is a nice gesture but not an FDA-verified guarantee of anything. Limitless Life Nootropics pitches to biohackers in a way that makes a needle-free PT-141 feel like a casual supplement, when it’s actually an unapproved research chemical carrying a real cardiovascular warning. Biotech Peptides is another research-only supplier with the same lack of oversight. Swiss Chems sells it next to other peptides and SARMs under research-use labeling, same missing screen, same baggage.

I can’t rank these against each other by quality, and honestly, neither can anyone reading this article, because without independent batch-level testing there’s no reliable way to know what’s actually in the vial or spray bottle. A nice-looking nasal spray doesn’t fix that uncertainty. That uncertainty, stacked with the absent screening, is exactly why the supervised tier sits above all of them, no matter which delivery form you’re comparing.

A few honest answers to the questions people actually ask me

Which PT-141 delivery form actually has evidence behind it? Just the subcutaneous injection. Vyleesi, the 1.75 mg autoinjector, is the form used in the RECONNECT Phase 3 trials [P1] [P3]. Nasal sprays, troches, and oral versions are compounded and weren’t part of that trial data, so their evidence base is thin to nonexistent. Picking a form is a comfort call, just be honest with yourself about which side of the evidence line you’re standing on.

Is a needle-free version actually safer than the shot? No, and this is the one I’d want a friend to tell me straight. The cardiovascular contraindication, the nausea, the pigmentation risk, all of it rides with the molecule, not the delivery method [P3] [P4]. A spray from a site that never asked about your blood pressure is not the safer choice just because there’s no needle involved. Form changes comfort. Source changes safety. Don’t let the two get tangled.

Does the form change whether it’s FDA-approved? Nope. Only the injectable brand, Vyleesi, carries FDA approval, and only for premenopausal women with HSDD [P2] [P3]. Every compounded version, spray, troche, oral, injectable made outside the brand, is not an approved finished product. A needle-free label doesn’t make it an approved one.

Okay, so where should I actually get this, whatever form I go with? A licensed telehealth provider that screens you for the cardiovascular contraindication and dispenses through a real pharmacy, not a research-chemical seller shipping you a vial with zero medical contact. By that measure, FormBlends comes in first and HealthRX.com second, both running roughly $90 to $250 a month for the supervised route. The research-chemical sellers, Pure Rawz, Core Peptides, Limitless Life Nootropics, Biotech Peptides, and Swiss Chems, all sit below that line, no matter how convenient their packaging looks.

What is PT-141 actually doing once it’s in your system?

Bremelanotide activates melanocortin receptors in your brain, MC3R and MC4R in particular, which play a role in sexual arousal. Unlike medications that work by adjusting blood flow, this one works centrally, on the nervous system itself. That distinction is why it can shift desire, not just physical response. The FDA approved the injectable version, Vyleesi, specifically for hypoactive sexual desire disorder in premenopausal women.

How long does it last, and when should you take it?

Most people report feeling effects for roughly 6 to 12 hours, with the peak usually somewhere in the 2 to 4 hour window after dosing. Timing shifts a bit by person and by form. The FDA-approved injection is labeled for use at least 45 minutes before you’d want it to matter. Nausea, the most common side effect, tends to show up in that same early window, so it’s worth planning around practically, not just emotionally.

How much do people typically take, and who’s supposed to decide that?

The FDA-approved Vyleesi dose is 1.75 mg by subcutaneous injection. Compounding pharmacies working under physician supervision sometimes prepare different strengths, but that call belongs to a prescribing clinician looking at your actual health history, not a dosage chart on a seller’s website. If you’re sourcing this without a prescription and guessing your own dose, you’ve got no accountability layer, no verified purity information, and nobody watching how your body responds. That’s the real risk sitting underneath the unregulated research-chemical route.

Does PT-141 do anything to testosterone?

No. It works through melanocortin receptors tied to arousal pathways, a completely different system from the hypothalamic-pituitary-gonadal axis that governs testosterone. If low testosterone is actually behind low libido, PT-141 isn’t addressing that piece at all. Some people use both under medical supervision for different reasons, but that’s not because PT-141 itself has any androgenic effect. Anyone selling it to you as a testosterone booster is misrepresenting the pharmacology, plain and simple.

References

1. Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and Gynecology, 2019 Nov;134(5):899-908. RECONNECT; 1,267 women randomized; subcutaneous form; integrated desire +0.35 and distress -0.33, both statistically significant. https://pubmed.ncbi.nlm.nih.gov/31599840/
2. FDA approval of Vyleesi (bremelanotide) for premenopausal women with acquired, generalized HSDD; approval letter, June 21, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
3. Vyleesi (bremelanotide) FDA-approved prescribing information: 1.75 mg subcutaneous autoinjector (the studied form); contraindication in uncontrolled hypertension or known cardiovascular disease; transient blood-pressure increase and heart-rate decrease; adverse reactions (nausea 40%, flushing ~20%, injection site reactions ~13%, headache ~11%, vomiting ~5%; anti-emetic 13%, discontinuation 8%); focal hyperpigmentation (~1% intermittent, 38% daily x8 days, higher risk in darker skin). (mirror:)
4. Bremelanotide mechanism (melanocortin receptor agonist, predominantly MC1R and MC4R), 2019 approval, route and dosing. NIH LiverTox monograph, NIDDK.

---

Written by Hassan Farrell, features writer. Reading the studies before believing the pitch. Last reviewed January 2026.

Not clinical advice. Discuss any changes with a licensed provider who knows your history.